COMPANY
CeQur
CeQur is listed on ClinicalTrials.gov as the lead sponsor of 3 studies; the most recently updated is “Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus” (no phase, completed), in Type 2 Diabetes Mellitus. From public records Source · Oct 12, 2026
Raises and deals from press releases
- Raise Series E · $100M · announced Jun 9, 2026 Company release ↗
Source quote
- Jun 9, 2026 · Company release ↗
“CeQur ® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity ™ Series E Financing Reflects Sustained Investor Confidence in CeQur’s Commercial Trajectory”
- Jun 9, 2026 · Company release ↗
- Raise Undisclosed round · $120M · announced Jan 7, 2025 Company release ↗
Source quote
- Jan 7, 2025 · Company release ↗
“CeQur ® , a medical device company dedicated to simplifying insulin delivery for individuals on multiple daily injections, today announced the successful close of a $120 million financing round”
- Jan 7, 2025 · Company release ↗
Timeline
- Partnership Partnership / licensing announced Sep 28, 2026. Source: company's own press page. source ↗
- Raise Private equity round — Series E: $100M (total, as published), announced Jun 9, 2026. Source: company's own press page. source ↗
- Raise Series E · $100M source ↗
- Raise Private equity round: $120M (total, as published), announced Jan 7, 2025. Source: company's own press page. source ↗
- Raise Undisclosed round · $120M source ↗
Funding
- Private equity round — Series E: $100M (total, as published), announced Jun 9, 2026. Source: company's own press page. source ↗
- Private equity round: $120M (total, as published), announced Jan 7, 2025. Source: company's own press page. source ↗
- Partnership / licensing announced Sep 28, 2026. Source: company's own press page. source ↗
Connect
See your connections at CeQur on LinkedIn (search by name, results not checked)